194 related articles for article (PubMed ID: 35117924)
1. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma.
Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X
Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924
[TBL] [Abstract][Full Text] [Related]
2. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
3. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
5. Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan.
Ali S; Rathore Z; Rafique Z; Chughtai AS; Atiq A
Cureus; 2022 Aug; 14(8):e27938. PubMed ID: 36120242
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical profile of triple negative breast cancers: SOX10 and AR dual negative tumors have worse outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; ():100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
7. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
9. [Expression of SOX10 and GATA3 in breast cancer and their significance].
Liu JL; Chen DS; Cheng ZQ; Hu JT
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
[No Abstract] [Full Text] [Related]
10. Role of SOX10 Immunohistochemical Expression in Diagnosing Triple Negative Breast Cancer and Its Correlation With Clinicopathological Features.
Tariq MU; Siddiqui MA; Ud Din N; Kayani N
Cureus; 2024 Apr; 16(4):e59276. PubMed ID: 38813332
[TBL] [Abstract][Full Text] [Related]
11. Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens.
Abdelwahed M; Yurtsever N; Savant D; Karam P; Gimenez C; Das K; Sheikh-Fayyaz S; Khutti S
J Am Soc Cytopathol; 2022; 11(6):345-351. PubMed ID: 36055933
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of combined application of GATA3, SOX10 and p16 in triple negative breast carcinomas].
Zhang DM; Zhai CJ; Feng XD; Wang CZ; Qiu JF; Wei JG
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):735-740. PubMed ID: 35280018
[No Abstract] [Full Text] [Related]
13. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
14. TRPS1 is a promising marker for all subtypes of breast cancer.
Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM
Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281
[TBL] [Abstract][Full Text] [Related]
15. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.
Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM
Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715
[TBL] [Abstract][Full Text] [Related]
16. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
17. Combination of GATA3, SOX-10, and PAX8 in a Comprehensive Panel to Diagnose Breast Cancer Metastases.
Na K; Woo HY; DO SI; Kim SW
In Vivo; 2022; 36(1):473-481. PubMed ID: 34972751
[TBL] [Abstract][Full Text] [Related]
18. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
19. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
20. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
